Merck KGaA (OTCMKTS:MKGAF – Get Free Report) shares gapped up before the market opened on Tuesday. The stock had previously closed at $157.9690, but opened at $167.1350. Merck KGaA shares last traded at $167.5490, with a volume of 84 shares trading hands.
Merck KGaA Stock Down 2.4%
The business’s 50 day moving average price is $159.64 and its 200-day moving average price is $154.54. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.84 and a current ratio of 1.31. The firm has a market capitalization of $21.10 billion, a PE ratio of 24.92 and a beta of 0.96.
Institutional Trading of Merck KGaA
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. MASTERINVEST Kapitalanlage GmbH acquired a new position in Merck KGaA during the second quarter worth $4,896,000. Puzo Michael J purchased a new position in shares of Merck KGaA during the second quarter worth $2,230,000. Somerville Kurt F acquired a new stake in shares of Merck KGaA in the second quarter valued at $1,997,000. Pinnacle Holdings LLC acquired a new stake in shares of Merck KGaA in the second quarter valued at $1,487,000. Finally, North Star Asset Management Inc. acquired a new stake in shares of Merck KGaA in the second quarter valued at $1,411,000. Hedge funds and other institutional investors own 0.10% of the company’s stock.
Merck KGaA Company Profile
Merck KGaA is a German science and technology company headquartered in Darmstadt, Germany. Founded in 1668, it is one of the world’s oldest operating pharmaceutical and chemical companies. The company operates under the name EMD Serono in the United States and Canada, where the Merck name is associated with a separate company.
Merck KGaA operates through three primary business sectors: Healthcare, Life Science and Electronics. Its Healthcare business develops and markets prescription medicines, including treatments in oncology, neurology and immunology, as well as fertility and other specialty-care products.
See Also
- Five stocks we like better than Merck KGaA
- GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall?
- Intercepting Growth: Karman Secures $218M Lockheed Martin Deal
- Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
- Chip Stocks Have Pulled Back—Here’s How 3 Semiconductor ETFs Stack Up for Investors
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
